Search

Your search keyword '"A. Vaporciyan"' showing total 501 results

Search Constraints

Start Over You searched for: Author "A. Vaporciyan" Remove constraint Author: "A. Vaporciyan" Database Unpaywall Remove constraint Database: Unpaywall
501 results on '"A. Vaporciyan"'

Search Results

1. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

2. Early Interventional Treatment of High Output Chyle Leak following Esophagectomy is Associated with Improved Survival

3. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

4. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

5. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

6. Abstract A022: Dissecting patterns of small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA

8. Association of Preoperative Lung Function with Complications after Lobectomy Using Race-Neutral and Race-Specific Normative Equations

10. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non–small cell lung cancer

11. OA22.04 BRIGHTSTAR Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC

12. MA15.04 Timing of Pre-Biopsy COVID-mRNA Vaccination and PD-L1 Expression in Advanced Non-Small Cell Lung Cancer

13. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC

14. Do resected colorectal cancer patients need early chest imaging? Impact of clinicopathologic characteristics on time to development of pulmonary metastases

15. Circulomic variables predict pathologic staging preoperatively in treatment-naïve non-small cell lung cancer

16. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer

18. Impact of travel distance on receipt of indicated adjuvant therapy in resected non–small cell lung cancer

19. Factors associated with receipt of pulmonary metastasectomy in patients with lung-limited metastatic colorectal cancer: Disparities in care and impact on overall survival

21. Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations

22. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC

23. Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease

24. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

25. Supplementary Figure S7 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

26. Supplementary Figure S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

27. Supplementary Figure S9 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

28. Data from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

29. Supplementary Figure S6 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

30. Supplementary Figure S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

31. Supplementary Figure S8 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

32. Supplementary Figure S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

33. Supplementary Figure S3 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

34. Supplementary Figure S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

35. Supplementary Figure S5 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

36. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

37. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy

38. Supplementary Figure S3 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

39. Supplementary Figure S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

40. Supplementary Figure S6 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

41. Supplementary Figure S8 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

42. Supplementary Figure S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

43. Supplementary Figure S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

44. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

45. Supplementary Figure S9 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

46. Supplementary Figure S7 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

47. Perspectives, risk factors, and coping mechanisms in patients with self-reported financial burden following lung cancer surgery

48. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience

49. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

50. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC

Catalog

Books, media, physical & digital resources